Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease

Journal of Gastroenterology

Volumn 43, Issue 9, 2008, Pages 670-678

  Uemura, Naomi ^a   Inokuchi, Hideto ^b   Serizawa, Hiroshi ^c   Chikama, Toshiharu ^d   Yamauchi, Masao ^e   Tsuru, Tomomi ^f   Umezu, Toru ^g   Urata, Toshiro ^h   Yurino, Nobuo ⁱ   Tanabe, Satoshi ^j   Yoshida, Tomoharu ^k   Kawamura, Susumu ^l   Murakami, Atsushi ^m   Yamamoto, Munemitsu ⁿ   Chiba, Tsutomu ^o  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KITASATO INSTITUTE HOSPITAL   (Japan)

^d Chikama Gastro Intestinal and Internal Medicine Clinic   (Japan)

^e Yamauchi Internal Medicine Clinic   (Japan)

^f Hakataeki Higashi Clinic   (Japan)

^g Umezu Clinic   (Japan)

^h Komonji Hospital   (Japan)

ⁱ Shinyukuhashi Hospital   (Japan)

^j KITASATO UNIVERSITY HOSPITAL   (Japan)

^k YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^l Kawamura Internal Medicine Clinic   (Japan)

^m Murakami Clinic   (Japan)

ⁿ FUKUOKA WAJIRO HOSPITAL   (Japan)

^o KYOTO UNIVERSITY   (Japan)

more..

Author keywords

Heartburn; Nonerosive reflux disease (NERD); Omeprazole

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL CHEMISTRY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GENOTYPE; HEARTBURN; HELICOBACTER PYLORI; HEMATOLOGY; HUMAN; JAPANESE; LARYNX PAIN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 52749088410     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2214-5     Document Type: Article

References (27)

1. Fujiwara Y, Higuchi K, Watanabe Y, Shiba M, Watanabe T, Tominaga K, et al. Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J Gastroenterol Hepatol 2005;20:26-29.
2. Hoshihara Y. Endoscopic findings of GERD (in Japanese with English abstract). Nippon Rinsho (Jpn J Clin Med) 2004;62:1459-1464.
3. Mishima I, Adachi K, Arima N, Amano K, Takashima T, Moritani M, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scandinavian J Gastroenterol 2005;40:1005-1009.
4. Okamoto K, Iwakiri R, Mori M, Hara M, Oda K, Danjo A, et al. Clinical symptoms in endoscopic reflux esophagitis: Evaluation in 8031 adult subjects. Dig Dis Sci 2003;48:2237-2241.
5. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004;22:108-114.
6. Wiklund I, Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998;30:19-27.
7. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(Suppl 2):S1-S16.
8. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-979.
9. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastrooesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-973.
10. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998;10:119-124.
11. Bate CM, Griffin SM, Keeling PW, Axon AT, Dronfield MW, Chapman RW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-555.
12. Fujiwara Y, Higuchi K, Nebiki H, Chono S, Uno H, Kitada K, et al. Famotidine vs. omeprazole: A prospective randomized multicentre trial to determine efficacy in non-erosive gastrooesophageal reflux disease. Aliment Pharmacol Ther 2005;21(Suppl 2):10-18.
13. Armstrong D. Review article: Gastric pH - the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 2004;20(Suppl 5):19-26.
14. Streets CG, DeMeester TR. Ambulatory 24-hour esophageal pH monitoring: why, when, and what to do. J Clin Gastroenterol 2003;37:14-22.
15. Schindlbeck NE, Klauser AG, Voderholzer WA, Müller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995;155:1808-1812.
16. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598.
17. Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005;50:2009-2018.
18. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:654-664.
19. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479.
20. Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol 2005;11:4291-4299.
21. Kinoshita Y, Kobayashi T, Kato M, Asahina K, Haruma K, Shimatani T, et al. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol 2006;41:554-561.
22. Amano Y, Ishimura N, Furuta K, Okita K, Masaharu M, Azumi T, et al. Interobserver agreement on classifying endoscopic diagnoses of nonerosive esophagitis. Endoscopy 2006;38:1032-1035.
23. Ohkusa T, Maekawa T, Arakawa T, Nakajima M, Fujimoto K, Hoshino E, et al. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther 2005;21:1331-1339.
24. Papa A, Urgesi R, Grillo A, Danese S, Guglielmo S, Reberto I, et al. Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD). Minerva Gastroenterol Dietol 2004;50:215-226.
25. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920.
26. Galmiche JP, Clouse RE, Bálint A, Cook IJ, Kahrilas PJ, Paterson WG, et al. Functional esophageal disorders. Gastroenterology 2006;130:1459-1465.
27. Joelson S, Joelson IB, Lundborg P, Walan A, Wallander MA. Safety experience from long-term treatment with omeprazole. Digestion 1992;51(Suppl 1):93-101.